Biotech

All Articles

BMS channels TIGIT, bowing out $200M bank on Agenus bispecific

.Bristol Myers Squibb is actually axing yet another big wager coming from the Caforio period, ending...

Nuvation halts BET inhibitor after considering phase 1 information

.After taking a look at phase 1 information, Nuvation Bio has actually made a decision to halt servi...

' Clinical intuitiveness' led FDA specialists to support Zevra's unusual ailment med

.Zevra Rehabs' rare illness medication seems to be to be on the course to authorization this loss af...

Pfizer takes $230M reached after axing failed DMD genetics therapy

.Pfizer's stage 3 Duchenne muscle dystrophy (DMD) gene treatment breakdown has gone a $230 million o...

AC Immune views 'landmark' possible in Alzheimer's drug information

.After more than 20 years of deal with neurodegenerative health conditions, Swiss biotech air condit...

GSK loses ph. 2 HPV vaccine over shortage of best-in-class prospective

.GSK has actually broken up a stage 2 human papillomavirus (HPV) injection from its pipe after deter...

OS Treatments refiles $6M IPO to fund HER2 drug, preclinical ADCs

.OS Therapies will detail on the NYSE American stock substitution today using a $6.4 thousand IPO th...

ALX's fizzling CD47 response cost sends stock spiraling down

.ALX Oncology's phase 2 stomach cancer reaction fee has deteriorated. After finding its own CD47 blo...

Ionis axes eye illness from intendeds of Roche-partnered possibility after records disappoint

.Yet Another of Ionis Pharmaceuticals' essential midphase readouts has actually disappointed expecta...

Biogen's CEO said no unsafe sell 2023. He's ready to be daring

.While Biogen's pharma peers are searching for late-stage resources with little risk, CEO Chris Vieh...